Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

A study by University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...

Four years ago, over dinner and drinks, five Buckhead moms hatched a bold plan to turn their love of softball into a lifeline for those battling Crohn’s disease.

Crohn's disease, a type of chronic inflammatory bowel disease (IBD), often causes scar-like tissue to build up in the ...

Nutrients specific to the Mediterranean diet could help with symptom management in inflammatory bowel disease, evidence ...